Navigation Links
IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"

NEW YORK, Jan. 22, 2013 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced that on January 17, 2013 the Company received a notice of allowance regarding its U.S. Patent Application Serial No. 13/323,030 entitled "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells." The allowed claims apply to IntelliCell's proprietary method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.

Steven Victor MD, Chairman and CEO of IntelliCell stated, "We are very excited to receive this notice of allowance from the US Patent Office.  We believe that this is a very significant milestone for the Company and for the advancement of regenerative medicine.  The fact that we can produce viable stromal vascular fraction cells, the regenerative cells of the human body, without resorting to the use of enzymes which have the potential to effect fundamental change on the cells, is a significant step forward in the potential uses of stromal vascular fraction cells for the treatment of serious disease states and conditions.  This patent and others in process will establish IntelliCell's position as a leader in the industry focused on the minimal manipulation of human tissues to be used for regenerative procedures.  We look forward to announcing additional upcoming milestones in our continuing mission to demonstrate the safety and efficacy of our cellular treatments to the scientific, medical, and consumer stakeholder communities under guidelines established by global regulators."

Added Robert Sexauer , EVP of Clinical Development at IntelliCell; "We are very pleased to announce the claim of allowances in our US patent utilizing ultrasonic sound waves, used safely medically for decades in multiple diagnostic and therapeutic purposes, to enhance our goals in Regenerative Medicine.  The IntelliSonics™ process, developed by IntelliCell, of producing minimally manipulated therapeutically active regenerative autologous (your own) cells may make very important contributions in treating a number of disease states where no cures are available today.  We look forward to working with groups of multi-disciplinary clinicians using this promising technology."             

About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs. The Company has several patent-pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into an ambulatory surgery center.

Investor Contact:
Jeff Ramson , CEO
ProActive Capital Group, LLC
641 Lexington Avenue, 6th Floor
New York, NY  10022
646-863-6893 office

SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IntelliCell BioSciences Announces FDA Registration for its Cell Processing Facility
2. IntelliCell BioSciences Files Patent Application for a New Mechanical Method to Separate Stromal Vascular Fraction from the Blood Vessels in Adipose Tissue
3. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
6. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
7. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
8. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
9. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
10. Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
11. 3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Post Your Comments:
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
(Date:11/25/2015)... plc (NYSE: AGN ) today announced that it has ... Attorney General,s Office to end the litigation under ... the Attorney General over the decision of Forest Laboratories, Inc., ... now generic version of memantine immediate release tablets.  Under the ... counterclaims against New York , and has ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is ... Pro X. With ProSidebar: Fasion, video editors can easily add an informative sidebar ... minimalist title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today that ... (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ERP ... partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment ...
(Date:11/27/2015)... ... 27, 2015 , ... Keeping in mind challenges faced by ... wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for ... parents and bring advice from parenting experts within their reach. As a part ...
Breaking Medicine News(10 mins):